SG11201704227QA - Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof - Google Patents

Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof

Info

Publication number
SG11201704227QA
SG11201704227QA SG11201704227QA SG11201704227QA SG11201704227QA SG 11201704227Q A SG11201704227Q A SG 11201704227QA SG 11201704227Q A SG11201704227Q A SG 11201704227QA SG 11201704227Q A SG11201704227Q A SG 11201704227QA SG 11201704227Q A SG11201704227Q A SG 11201704227QA
Authority
SG
Singapore
Prior art keywords
fxr
methods
acid derivatives
bile acid
tgr5 agonists
Prior art date
Application number
SG11201704227QA
Inventor
Guoqiang Wang
Yat Sun Or
Ruichao Shen
Jiang Long
Peng Dai
Xuechao Xing
Jing He
Original Assignee
Enanta Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Enanta Pharm Inc filed Critical Enanta Pharm Inc
Publication of SG11201704227QA publication Critical patent/SG11201704227QA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0066—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by a carbon atom forming part of an amide group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0088—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing unsubstituted amino radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/006—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton spiro-condensed
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0094—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing nitrile radicals, including thiocyanide radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
SG11201704227QA 2014-11-26 2015-11-27 Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof SG11201704227QA (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201462084769P 2014-11-26 2014-11-26
US201562103374P 2015-01-14 2015-01-14
US14/951,989 US10208081B2 (en) 2014-11-26 2015-11-25 Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
PCT/US2015/062826 WO2016086218A1 (en) 2014-11-26 2015-11-27 Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof

Publications (1)

Publication Number Publication Date
SG11201704227QA true SG11201704227QA (en) 2017-06-29

Family

ID=56075071

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201909545X SG10201909545XA (en) 2014-11-26 2015-11-27 Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof
SG11201704227QA SG11201704227QA (en) 2014-11-26 2015-11-27 Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG10201909545X SG10201909545XA (en) 2014-11-26 2015-11-27 Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof

Country Status (26)

Country Link
US (5) US10208081B2 (en)
EP (1) EP3223822B1 (en)
JP (1) JP6857124B2 (en)
KR (1) KR102543268B1 (en)
CN (1) CN107106575B (en)
AU (1) AU2015353372B2 (en)
CA (1) CA2968673C (en)
CY (1) CY1123595T1 (en)
DK (1) DK3223822T3 (en)
ES (1) ES2815624T3 (en)
HK (1) HK1244707A1 (en)
HR (1) HRP20201420T1 (en)
HU (1) HUE051971T2 (en)
IL (2) IL252449A0 (en)
LT (1) LT3223822T (en)
MX (1) MX2017006832A (en)
NZ (1) NZ732154A (en)
PH (1) PH12017500941A1 (en)
PL (1) PL3223822T3 (en)
PT (1) PT3223822T (en)
RS (1) RS60836B1 (en)
RU (1) RU2707280C2 (en)
SG (2) SG10201909545XA (en)
SI (1) SI3223822T1 (en)
WO (1) WO2016086218A1 (en)
ZA (2) ZA201704154B (en)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2545964A1 (en) 2011-07-13 2013-01-16 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
SG11201703717SA (en) 2014-11-06 2017-06-29 Enanta Pharm Inc Bile acid analogs an fxr/tgr5 agonists and methods of use thereof
WO2016079518A1 (en) 2014-11-19 2016-05-26 Dextra Laboratories Limited 5.beta.-6-alkyl-7-hydroxy-3-one steroids as intermediates for the production of steroidal fxr modulators
DK3221331T3 (en) 2014-11-19 2019-12-02 Nzp Uk Ltd 6-ALKYL-7-HYDROXY-4-EN-3-ON STEROIDS AS INTERMEDIATES FOR THE MANUFACTURE OF STEROID FXR MODULATORS
CN107108688B (en) 2014-11-19 2019-10-29 Nzp英国有限公司 6 alpha-alkyl -3,7- diketone the steroids as the intermediate for preparing steroids FXR regulator
JP6698085B2 (en) 2014-11-19 2020-05-27 エヌゼットピー ユーケー リミテッド 6α-Alkyl-6,7-dione-steroids as intermediates for the production of steroid FXR modulators
US10208081B2 (en) 2014-11-26 2019-02-19 Enanta Pharmaceuticals, Inc. Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
CN107231795A (en) 2014-11-26 2017-10-03 英安塔制药有限公司 It is used as the bile acid analog and its application method of FXR/TGR5 activators
US11578097B2 (en) 2014-11-26 2023-02-14 Enanta Pharmaceuticals, Inc. Tetrazole derivatives of bile acids as FXR/TGR5 agonists and methods of use thereof
SG10201910670RA (en) 2015-03-31 2020-01-30 Enanta Pharm Inc Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof
TW201700447A (en) * 2015-06-19 2017-01-01 英特賽普醫藥品公司 TGR5 modulators and methods of use thereof
US10800807B2 (en) 2015-06-19 2020-10-13 Intercept Pharmaceuticals, Inc. TGR5 modulators and methods of use thereof
BR112018015474A2 (en) * 2016-01-28 2018-12-18 Chia Tai Tianqing Pharmaceutical Group Co., Ltd Steroid Derivatives FXR Agonists
US10323060B2 (en) 2016-02-23 2019-06-18 Enanta Pharmaceuticals, Inc. Benzoic acid derivatives of bile acid as FXR/TGR5 agonists and methods of use thereof
US10323061B2 (en) 2016-02-23 2019-06-18 Enanta Pharmaceuticals, Inc. Heteroaryl containing bile acid analogs as FXR/TGR5 agonists and methods of use thereof
WO2017147159A1 (en) 2016-02-23 2017-08-31 Enanta Pharmaceuticals, Inc. Deuterated bile acid derivatives as fxr/tgr5 agonists and methods of use thereof
EA038580B9 (en) * 2016-05-18 2021-10-05 Чиа Тай Тяньцин Фармасьютикал Груп Ко., Лтд. Steroid derivative fxr agonist
GB201608777D0 (en) 2016-05-18 2016-06-29 Dextra Lab Ltd Compounds
CA2968836A1 (en) 2016-06-13 2017-12-13 Gilead Sciences, Inc. Fxr (nr1h4) modulating compounds
WO2017218337A1 (en) 2016-06-13 2017-12-21 Gilead Sciences, Inc. Fxr (nr1h4) modulating compounds
CN108017636A (en) 2016-11-04 2018-05-11 合帕吉恩治疗公司 Nitrogen-containing heterocycle compound as FXR conditioning agents
JP7057783B2 (en) * 2016-11-29 2022-04-20 エナンタ ファーマシューティカルズ インコーポレイテッド Method for preparing sulfonylurea bile acid derivative
US10472386B2 (en) 2017-02-14 2019-11-12 Enanta Pharmaceuticals, Inc. Bile acid derivatives as FXR agonists and methods of use thereof
SG11201906987RA (en) 2017-02-21 2019-09-27 Genfit Combination of a ppar agonist with a fxr agonist
ES2927019T3 (en) 2017-03-28 2022-11-02 Gilead Sciences Inc Therapeutic combinations for the treatment of liver diseases
US10676500B2 (en) 2017-04-07 2020-06-09 Enanta Pharmaceuticals, Inc. Process for preparation of sulfonyl carbamate bile acid derivatives
EP3642217A4 (en) 2017-06-23 2021-06-16 Intercept Pharmaceuticals, Inc. Methods and intermediates for the preparation of bile acid derivatives
KR20200041337A (en) * 2017-08-15 2020-04-21 인플라좀 리미티드 Novel sulfonamide carboxamide compounds
CN109929005B (en) * 2017-12-19 2020-10-30 西安奥立泰医药科技有限公司 Compound for treating metabolic diseases and preparation method and application thereof
GEP20227409B (en) 2018-05-01 2022-09-12 Merck Sharp & Dohme Spiropiperidine allosteric modulators of nicotinic acetylcholine receptors
GB201812382D0 (en) 2018-07-30 2018-09-12 Nzp Uk Ltd Compounds
SG11202107434PA (en) 2019-01-15 2021-08-30 Gilead Sciences Inc Fxr (nr1h4) modulating compounds
EP3927683A1 (en) 2019-02-19 2021-12-29 Gilead Sciences, Inc. Solid forms of fxr agonists
WO2023288123A1 (en) 2021-07-16 2023-01-19 Interecept Pharmaceuticals, Inc. Methods and intermediates for the preparation of 3.alpha.,7.alpha.,11.beta.-trihydroxy-6.alpha.-ethyl-5.beta.-cholan-24-oic acid
TW202333741A (en) * 2021-11-15 2023-09-01 大陸商海湃泰克（北京）生物醫藥科技有限公司 Polycyclic compounds and methods thereof

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1592791A (en) 1977-01-07 1981-07-08 Radiochemical Centre Ltd Selenium- or tellurium-containing bile acids and derivatives thereof
US4917826A (en) 1985-10-18 1990-04-17 The Upjohn Company Cyclic hydrocarbons with an aminoalkyl sidechain
IT1255449B (en) 1992-06-30 1995-10-31 Fabio Berlati USE OF NOR- AND HOMO-DERIVATIVES OF BILE ACIDS AS DRUGS ABSORPTION PROMOTERS.
IT1255485B (en) 1992-08-04 1995-11-06 Erregierre Ind Chim PROCESS TO PREPARE GLYCINE CONJUGATED BILIARY ACIDS AND RELATED THERAPEUTIC COMPOSITIONS FOR THE TREATMENT OF HEPATIC INSUFFICIENCY
TW289020B (en) 1993-05-08 1996-10-21 Hoechst Sktiengesellschaft
TW289757B (en) 1993-05-08 1996-11-01 Hoechst Ag
US5541348A (en) 1994-03-10 1996-07-30 National Research Council Of Canada Bile acids for biological and chemical applications and processes for the production thereof
ATE372966T1 (en) 1994-03-25 2007-09-15 Isotechnika Inc IMPROVED EFFECTIVENESS OF DRUGS THROUGH DEUTERATION
US5646316A (en) 1994-04-08 1997-07-08 Osteoarthritis Sciences, Inc. Bile acid inhibitors of metalloproteinase enzymes
JPH1160594A (en) 1997-08-25 1999-03-02 Sankyo Co Ltd Bile acid derivative
JP3865890B2 (en) 1997-09-30 2007-01-10 富士フイルムホールディングス株式会社 Positive photosensitive composition
AU2389100A (en) 1998-12-23 2000-07-12 Glaxo Group Limited Assays for ligands for nuclear receptors
US20020132223A1 (en) 1999-03-26 2002-09-19 City Of Hope Methods for modulating activity of the FXR nuclear receptor
ATE442360T1 (en) 2000-07-26 2009-09-15 Us Gov Health & Human Serv 5-SUBSTITUTED PYRIMIDINE DERIVATIVES OF A CONFORMATIO-FIXED NUCLEOSIDE ANALOGO
US20020098999A1 (en) 2000-10-06 2002-07-25 Gallop Mark A. Compounds for sustained release of orally delivered drugs
WO2002028881A1 (en) 2000-10-06 2002-04-11 Xenoport, Inc. Bile-acid derived compounds for providing sustained systemic concentrations of drugs after oral administration
WO2002072598A1 (en) 2001-03-12 2002-09-19 Roberto Pellicciari Steroids as agonists for fxr
DE60131967D1 (en) 2001-08-13 2008-01-31 Phenex Pharmaceuticals Ag Nr1h4 nuclear receptor binding compounds
WO2003086303A2 (en) 2002-04-12 2003-10-23 The University Of Chicago Farnesoid x-activated receptor agonists
ITMI20021080A1 (en) 2002-05-21 2003-11-21 Marcello Izzo PHARMACEUTICAL ASSOCIATIONS FOR TOPICAL USE BASED ON CHELATES OF THE METAL PROTEASIS FERROINHIBITORS AND FACTOR XIII FOR THE TREATMENT OF
EP1562915A1 (en) 2002-11-22 2005-08-17 SmithKline Beecham Corporation Farnesoid x receptor agonists
EP1568706A1 (en) 2004-02-26 2005-08-31 Intercept Pharmaceuticals, Inc. Novel steroid agonist for FXR
PT2712617T (en) 2004-03-12 2017-02-13 Intercept Pharmaceuticals Inc Treatment of fibrosis using fxr ligands
WO2006113204A2 (en) 2005-04-15 2006-10-26 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Thymidine derivatives for treatmemt of kaposi's sarcoma
ITMI20050912A1 (en) 2005-05-19 2006-11-20 Erregierre Spa PROCESS OF PREPARATION OF ACIDS 3-A-YA (B) -DIDROSSI-6-A (B) -ALCHIL-5B-COLANICI
ATE526318T1 (en) 2005-12-19 2011-10-15 Glaxosmithkline Llc FARNESOID-X RECEPTOR AGONISTS
US20070190067A1 (en) * 2006-02-01 2007-08-16 Savage Paul B Cationic Steroid Antimicrobial Compositions and Methods of Use
JP5301286B2 (en) 2006-02-03 2013-09-25 イーライ リリー アンド カンパニー Compounds and methods for modulating FX receptors
BRPI0707794A2 (en) * 2006-02-14 2011-05-10 Intercept Pharmaceuticals Inc bile acid derivatives, formulations and pharmaceutical compositions, as well as use of said compounds
AU2007230991A1 (en) 2006-03-22 2007-10-04 Syndexa Pharmaceuticals Corporation Compounds and methods for treatment of disorders associated with ER stress
MX2008014959A (en) 2006-05-24 2008-12-09 Lilly Co Eli Compounds and methods for modulating fxr.
EA015632B9 (en) 2006-05-24 2012-08-30 Эли Лилли Энд Компани Fxr agonists
EP2040713B1 (en) 2006-06-27 2014-06-18 Intercept Pharmaceuticals Inc. Bile acid derivatives as fxr ligands for the prevention or treatment of fxr-mediated deseases or conditions
WO2008009407A2 (en) 2006-07-17 2008-01-24 Novartis Ag Sulphonylaminocarbonyl derivatives of bile acid amides for use as immunomodulators
EP1894928A1 (en) 2006-08-29 2008-03-05 PheneX Pharmaceuticals AG Heterocyclic fxr binding compounds
EP1894924A1 (en) 2006-08-29 2008-03-05 Phenex Pharmaceuticals AG Heterocyclic FXR binding compounds
CL2007003035A1 (en) 2006-10-24 2008-05-16 Smithkline Beechman Corp COMPOUNDS DERIVED FROM ISOXAZOL REPLACED, FARNESOID X RECEIVER AGONISTS; PREPARATION PROCEDURE; PHARMACEUTICAL COMPOSITION THAT UNDERSTANDS IT; AND USE OF THE COMPOUND IN THE TREATMENT OF OBESITY, DIABETES MELLITUS, FIBROSIS IN ORGANS,
MX2009007728A (en) * 2007-01-19 2009-12-15 Intercept Pharmaceuticals Inc 23-substituted bile acids as tgr5 modulators and methods of use thereof.
EP1947108A1 (en) 2007-01-19 2008-07-23 Intercept Pharmaceuticals, Inc. TGR5 modulators and methods of use thereof
EP2125757A1 (en) 2007-02-20 2009-12-02 Novartis AG Macrocyclic compounds as hcv ns3 protease inhibitors
AU2008266154A1 (en) 2007-06-13 2008-12-24 Claxosmithkltne Llc Farnesoid X receptor agonists
AU2008270784A1 (en) 2007-07-02 2009-01-08 Glaxosmithkline Llc Farnesoid X receptor agonists
TW200906823A (en) 2007-07-16 2009-02-16 Lilly Co Eli Compounds and methods for modulating FXR
US8338628B2 (en) 2007-08-28 2012-12-25 City Of Hope Method of synthesizing alkylated bile acid derivatives
EP2188299B1 (en) 2007-09-06 2017-10-25 Ohr Pharmaceutical, Inc. Compounds for treating diabetes
US20090163474A1 (en) 2007-10-19 2009-06-25 Wyeth FXR Agonists for the Treatment of Nonalcoholic Fatty Liver and Cholesterol Gallstone Diseases
KR101239008B1 (en) 2008-03-31 2013-03-04 한양대학교 산학협력단 Bile acid derivatives and their applications
BRPI0916735B8 (en) 2008-07-30 2021-05-25 Intercept Pharmaceuticals Inc tgr5 modulating compounds, pharmaceutical compositions comprising them and their uses
WO2010030858A1 (en) 2008-09-15 2010-03-18 Enanta Pharmaceuticals, Inc. 4'-allene-substituted nucleoside derivatives
US8603737B2 (en) 2008-09-19 2013-12-10 Celgene Avilomics Research, Inc. Methods for identifying HCV protease inhibitors
CN102395567A (en) * 2009-02-12 2012-03-28 埃克塞利希斯股份有限公司 Triazole and imidazole derivatives for use as tgr5 agonists in the treatment of diabetes and obesity
EP2289883A1 (en) 2009-08-19 2011-03-02 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
EP2545964A1 (en) 2011-07-13 2013-01-16 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
WO2013020108A2 (en) 2011-08-04 2013-02-07 Lumena Pharmaceuticals, Inc. Bile acid recycling inhibitors for treatment of pancreatitis
US11154559B2 (en) 2011-09-29 2021-10-26 Ethicon Endo-Surgery, Inc. Methods and compositions of bile acids
AU2013256362A1 (en) 2012-05-01 2014-11-13 Catabasis Pharmaceuticals, Inc. Fatty acid conjugates of statin and FXR agonists: compositions and methods of use
BR122016011808B1 (en) 2012-06-19 2021-09-21 Intercept Pharmaceuticals, Inc PROCESSES FOR PREPARING OBETICOLIC ACID FORM 1 AND CRYSTALLINE OBETICOLIC ACID
TWI610916B (en) 2012-08-03 2018-01-11 廣東東陽光藥業有限公司 Bridged ring compounds as hepatitis c virus (hcv) inhibitors and pharmaceuticals applications thereof
US9079935B2 (en) 2012-08-13 2015-07-14 The Board Of Regents Of The Nevada System Of Higher Education On Behalf Of The University Of Nevada, Las Vegas Reducing risk of contracting Clostridium-difficile associated disease
WO2014036377A1 (en) 2012-08-31 2014-03-06 Metselex Methods of promoting cell viability
US20140187633A1 (en) 2012-12-31 2014-07-03 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
US9814733B2 (en) 2012-12-31 2017-11-14 A,arin Pharmaceuticals Ireland Limited Compositions comprising EPA and obeticholic acid and methods of use thereof
US20140206657A1 (en) 2013-01-18 2014-07-24 City Of Hope Bile acid analog tgr5 agonists
DK3360881T3 (en) 2013-05-14 2021-03-15 Intercept Pharmaceuticals Inc 11-hydroxy-6-substituted derivatives of bile acids and amino acid conjagates thereof as farnesoid X receptor modulators
WO2015017813A2 (en) 2013-08-01 2015-02-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Inhibitors of the farnesoid x receptor and uses in medicine
US20150112089A1 (en) 2013-10-22 2015-04-23 Metselex, Inc. Deuterated bile acids
CA2948585C (en) 2014-05-29 2022-07-26 Bar Pharmaceuticals S.R.L. Cholane derivatives for use in the treatment and/or prevention of fxr and tgr5/gpbar1 mediated diseases
SG11201703717SA (en) 2014-11-06 2017-06-29 Enanta Pharm Inc Bile acid analogs an fxr/tgr5 agonists and methods of use thereof
CN105669811B (en) 2014-11-17 2020-09-04 正大天晴药业集团股份有限公司 New 7-keto-6 beta-alkyl cholanic acid derivative in preparation of obeticholic acid and application thereof in medical field
CN107231795A (en) 2014-11-26 2017-10-03 英安塔制药有限公司 It is used as the bile acid analog and its application method of FXR/TGR5 activators
WO2016086134A1 (en) * 2014-11-26 2016-06-02 Enanta Pharmaceuticals, Inc. Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof
US10208081B2 (en) 2014-11-26 2019-02-19 Enanta Pharmaceuticals, Inc. Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
US20160176917A1 (en) 2014-11-26 2016-06-23 Enanta Pharmaceuticals, Inc. Bile Acid Derivatives as FXR/TGR5 Agonists and Methods of Use Thereof
US11578097B2 (en) 2014-11-26 2023-02-14 Enanta Pharmaceuticals, Inc. Tetrazole derivatives of bile acids as FXR/TGR5 agonists and methods of use thereof
JP2018505190A (en) 2015-02-11 2018-02-22 エナンタ ファーマシューティカルズ インコーポレイテッド Bile acid analogs as FXR / TGR5 agonists and methods of use thereof
SG10201910670RA (en) 2015-03-31 2020-01-30 Enanta Pharm Inc Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof
CN111116699B (en) 2015-04-28 2023-02-28 江苏豪森药业集团有限公司 Cholic acid derivative and preparation method and medical application thereof
WO2016173493A1 (en) 2015-04-28 2016-11-03 Shanghai De Novo Pharmatech Co. Ltd. Sulfonylaminocarbonyl derivative, pharmaceutical composition and uses thereof
TW201704251A (en) 2015-04-29 2017-02-01 正大天晴藥業集團股份有限公司 Derivatives of chenodeoxycholic acid
TW201700447A (en) 2015-06-19 2017-01-01 英特賽普醫藥品公司 TGR5 modulators and methods of use thereof
CA2994687A1 (en) 2015-08-07 2017-02-16 Intercept Pharmaceuticals, Inc. Methods for preparation of bile acids and derivatives thereof
CN105175473B (en) 2015-08-19 2018-12-21 丽珠医药集团股份有限公司 A kind of Austria shellfish cholic acid crystal form I and preparation method thereof, pharmaceutical composition and purposes
CN106478759A (en) 2015-08-31 2017-03-08 陕西合成药业股份有限公司 Shellfish chlolic acid derivatives difficult to understand and its production and use
CN106518946A (en) 2015-09-10 2017-03-22 上海迪诺医药科技有限公司 Sulfonylurea derivative and pharmaceutical composition and application thereof
KR20180052756A (en) 2015-09-24 2018-05-18 인터셉트 파마슈티컬즈, 인크. Methods and intermediates for the preparation of bile acid derivatives
US11034717B2 (en) 2015-10-07 2021-06-15 Intercept Pharmaceuticals, Inc. Farnesoid X receptor modulators
BR112018015474A2 (en) 2016-01-28 2018-12-18 Chia Tai Tianqing Pharmaceutical Group Co., Ltd Steroid Derivatives FXR Agonists
US10323061B2 (en) 2016-02-23 2019-06-18 Enanta Pharmaceuticals, Inc. Heteroaryl containing bile acid analogs as FXR/TGR5 agonists and methods of use thereof
WO2017147159A1 (en) 2016-02-23 2017-08-31 Enanta Pharmaceuticals, Inc. Deuterated bile acid derivatives as fxr/tgr5 agonists and methods of use thereof
US10323060B2 (en) 2016-02-23 2019-06-18 Enanta Pharmaceuticals, Inc. Benzoic acid derivatives of bile acid as FXR/TGR5 agonists and methods of use thereof
MX2018010983A (en) 2016-03-11 2019-01-21 Intercept Pharmaceuticals Inc 3-desoxy derivative and pharmaceutical compositions thereof.
BE1025121B1 (en) 2016-11-17 2018-11-05 Glaxosmithkline Biologicals Sa ANTIGENIC CONSTRUCTS OF ZIKA VIRUS
JP7057783B2 (en) 2016-11-29 2022-04-20 エナンタ ファーマシューティカルズ インコーポレイテッド Method for preparing sulfonylurea bile acid derivative
US10472386B2 (en) 2017-02-14 2019-11-12 Enanta Pharmaceuticals, Inc. Bile acid derivatives as FXR agonists and methods of use thereof
US10676500B2 (en) 2017-04-07 2020-06-09 Enanta Pharmaceuticals, Inc. Process for preparation of sulfonyl carbamate bile acid derivatives

Also Published As

Publication number Publication date
KR102543268B1 (en) 2023-06-13
ES2815624T3 (en) 2021-03-30
HRP20201420T1 (en) 2020-12-11
NZ732154A (en) 2022-10-28
JP2017536379A (en) 2017-12-07
US20160185815A1 (en) 2016-06-30
RU2017120970A (en) 2018-12-26
ZA201704154B (en) 2020-03-25
EP3223822B1 (en) 2020-07-01
EP3223822A4 (en) 2018-07-11
PT3223822T (en) 2020-08-31
US10696713B2 (en) 2020-06-30
RU2017120970A3 (en) 2018-12-26
PH12017500941A1 (en) 2017-11-20
SG10201909545XA (en) 2019-11-28
HUE051971T2 (en) 2021-04-28
JP6857124B2 (en) 2021-04-14
WO2016086218A1 (en) 2016-06-02
CA2968673C (en) 2023-07-11
US10968249B2 (en) 2021-04-06
HK1244707A1 (en) 2018-08-17
DK3223822T3 (en) 2020-09-07
US20210261600A1 (en) 2021-08-26
US20240140984A1 (en) 2024-05-02
ZA201908293B (en) 2021-04-28
MX2017006832A (en) 2018-02-13
LT3223822T (en) 2020-10-12
US20200347092A1 (en) 2020-11-05
CA2968673A1 (en) 2016-06-02
IL252449A0 (en) 2017-07-31
US20190194245A1 (en) 2019-06-27
SI3223822T1 (en) 2020-11-30
US10208081B2 (en) 2019-02-19
KR20170087935A (en) 2017-07-31
EP3223822A1 (en) 2017-10-04
PL3223822T3 (en) 2021-01-11
RS60836B1 (en) 2020-10-30
CN107106575B (en) 2021-04-13
CN107106575A (en) 2017-08-29
RU2707280C2 (en) 2019-11-26
IL273567A (en) 2020-05-31
AU2015353372B2 (en) 2020-07-23
CY1123595T1 (en) 2022-03-24
BR112017011126A2 (en) 2018-01-23
US11718641B2 (en) 2023-08-08
AU2015353372A1 (en) 2017-06-15

Similar Documents

Publication Publication Date Title
ZA201908293B (en) Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof
ZA202102769B (en) Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof
HK1244708A1 (en) Bile acid analogs as fxr/tgr5 agonists and methods of use thereof
HK1243930A1 (en) Bile acid analogs an fxr/tgr5 agonists and methods of use thereof
HK1245100A1 (en) Bile acid analogs as fxr/tgr5 agonists and methods of use thereof
IL252596A0 (en) Azabicyclooctane derivatives as fxr agonists for use in the treatment of liver and gastrointestinal diseases
IL247529A0 (en) Lipoic acid choline ester compositions and methods of use
SG10201709955PA (en) Methods of treatment and compositions with xanthine oxidase inhibitors
SG11201605915WA (en) Furo-3-carboxamide derivatives and methods of use
HK1232209A1 (en) Method for the preparation of (s)-2-acetyloxypropionic acid and derivatives thereof (s)-2-
GB201408738D0 (en) Components and methods for formulation of components